Menopause Medicine Meets Obesity Care: Doctors React
Does menopausal hormone therapy change how women respond to GLP-1 medicines like tirzepatide and semaglutide? In this episode, Dr. Spencer Nadolsky and Dr. Karl Nadolsky sit down with Mayo Clinic’s Dr. Maria Daniela Hurtado Andrade and Dr. Regina Castaneda to discuss their latest research, the nuances behind the findings, and what it means for women navigating menopause and obesity care. Do you also want me to generate a few alternative title options that highlight their names (for authority) while still keeping the engagement factor?
Audio is streamed directly from the publisher (injector.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Takeaways
Menopausal women often prioritize weight gain concerns over other symptoms.
The study observed an association between hormone therapy and weight loss with GLP-1 medications.
Retrospective studies have limitations but can provide valuable insights.
Future research should focus on randomized controlled trials to confirm findings.
The relationship between estrogen and GLP-1 signaling needs further exploration.
Funding for research can be challenging, especially for early career investigators.
Collaboration between different specialties is crucial for comprehensive patient care.
The media often misrepresents research findings, leading to misconceptions.
Individualized treatment plans are essential for menopausal women.
There is a need for more awareness about the effects of menopause on health.
Research Links:
Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use
Combination of obesity medication tirzepatide and menopause hormone therapy fuels weight loss
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.